Pfizer's Acquisition Aims Can't Prop up the Dow

Goldman Sachs and the financial sector tumble today as the Dow Jones loses early momentum to stay just over breakeven.

Apr 28, 2014 at 2:30PM
Daily Fool

After a great start to the day, the market has lost all of its early momentum, with the Dow Jones Industrial Average (DJINDICES:^DJI) falling into the red before heading back up 17 points as of 2:30 p.m. EDT. Goldman Sachs (NYSE:GS) was leading the Dow's laggards in shedding 2.2%, part of a decline around the financial industry today. Meanwhile, Pfizer (NYSE:PFE) made big news by confirming its interest in AstraZeneca (NYSE:AZN) in what could be the beginnings of a titanic merger in the pharmaceutical industry. Let's catch up on what you need to know.

Goldman, financials on the downswing

Goldman Sachs Logo

Goldman Sachs is continuing what's been a horrible year so far for this leading bank. While this stock trades cheaply compared to its industry peers on both a price-to-earnings and price-to-book ratio, as measured by Motley Fool CAPS, shares have struggled to make the most of the market's rally over the past year. The increasing scrutiny of the financial sector no doubt warrants caution, but among the biggest banks, Goldman has managed to post investor-friendly results as of late.

Industry peers have struggled with turbulence from mortgages and lending, problems the trading-centered Goldman has managed to avoid -- although the company's suffered a fall in its fixed-income business following the financial sector's decline in the space. Still, Goldman's strength in its investment banking arm, which posted its best quarter since 2007 in the bank's most recent earnings report, makes this stock an attractive pick to watch considering its year-to-date slump.

The big Dow news today, however, comes from Pfizer. The stock has jumped about 3.5% so far after the company announced that it is indeed still chasing an acquisition of rival AstraZeneca. It's a potential merger of unprecedented size in the industry, with Pfizer offering nearly $99 billion in its latest proposal -- although AstraZeneca considers that offer too low for the company's value. In turn, AstraZeneca's stock has roared higher today by nearly 11%.

Pfizer's chief reason for pursuing AstraZeneca comes from the company's up-and-coming pipeline of drugs, particularly its portfolio of developmental cancer therapies. While many of these drugs are years from possible regulatory approval, they offer a potential counterweight to Pfizer's loss of patent exclusivity of former top-selling drug Lipitor. Pfizer's newest blockbuster hopefuls -- blood thinner Eliquis and rheumatoid arthritis treatment Xeljanz -- have hit the market slowly so far, and while the potential exists for huge sales in the future, anxious investors have clamored for better growth from this pharma giant.

Another tantalizing possibility for Pfizer exists in the acquisition of the British company. The merger would lead to Pfizer incorporating outside of the U.S., according to Bloomberg, thus avoiding U.S. taxes for repatriating money held abroad. Pfizer holds nearly $70 billion in foreign cash that it hasn't brought back to the U.S.; using those assets as part of an AstraZeneca acquisition would give the company an important edge over American Big Pharma rivals in the international battle for drug sales.

Is Pfizer a top dividend stock for the next decade?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Goldman Sachs. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers